Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 26, 2018
Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen® Tinnitus Program on March 5, 2018
Zug, Switzerland, February 26, 2018 - Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in ...
February 23, 2018
Pernix Therapeutics to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 8
MORRISTOWN, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company, announced today that the Company will report financial ...
February 23, 2018
DURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference Call
CUPERTINO, Calif., Feb. 22, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (DRRX) fourth quarter 2017 financial results press release, you are invited to listen to ...
February 23, 2018
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress
SAN DIEGO, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (LJPC), a leader in the development of innovative therapies intended to significantly ...
February 23, 2018
Addex Publishes Extraordinary General Meeting Invitation
Geneva, Switzerland, 23 February 2018 - Addex Therapeutics (ADXN.SW), the leading developer of oral allosteric modulators for neurological disorders, announced today that it has published ...
February 23, 2018
Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
Basel, Switzerland, February 23, 2018   Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that it has commenced enrollment in the first of its two planned clinical phase ...
February 23, 2018
Vermillion to Present at the 2018 BTIG Healthcare Conference
AUSTIN, Texas, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President ...
February 22, 2018
TRACON to Report Fourth Quarter and Full Year 2017 Company Highlights and Financial Results on February 28, 2018
SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
February 22, 2018
Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the pricing of an underwritten public offering ...
February 22, 2018
Santhera Completes Capital Increase to Settle Obtained License from Polyphor
Pratteln, Switzerland, February 22, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that its share capital recorded in the commercial register was increased from 6,279,857 shares by 247,622 ...
February 22, 2018
BioTime Appoints Cavan Redmond to Its Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, announced the appointment of Cavan Redmond as an ...
February 22, 2018
Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and ...
February 22, 2018
Advaxis Prices $20.0 Million Public Offering of Common Stock
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (ADXS), a late-stage biotechnology company (“Advaxis” or the “Company”) focused on the discovery, development and commercialization of cancer immunotherapies, announced today the ...
February 21, 2018
AIT Therapeutics Appoints Two Senior Executives in Research and Clinical Operations
NEW YORK, Feb. 20, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the ...
February 21, 2018
Spring Bank Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial and Operational Results
HOPKINTON, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
February 21, 2018
Prometic Announces Realignment of its Clinical Program Priorities for 2018
LAVAL, QC , Feb. 20, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic") today provided an update regarding its clinical development programs and ...
February 21, 2018
Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
Basel, Switzerland, February 21, 2018 - Basilea Pharmaceutica Ltd. (SIX:BSLN) reported today that Chief Executive Officer Ronald Scott will retire after 18 years with the ...
February 21, 2018
Zealand Pharma reports completion of the first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia
Copenhagen, February 21, 2018 - Zealand Pharma A/S ("Zealand") announces that the multinational Phase 3 clinical trial of dasiglucagon in four countries (Austria, Germany, Canada and ...
February 21, 2018
Gemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH
LIVONIA, Mich., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
February 21, 2018
Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting
VANCOUVER, Feb. 21, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) ...
Page 64 of 117